• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study.

作者信息

Gyldenløve Mette, Nissen Christoffer Valdemar, Stave Sascha Dinsen Wreschner, Thomsen Simon Francis, Egeberg Alexander, Loft Nikolai

机构信息

Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Hospitalsvej 15, 2900, Hellerup, Denmark.

Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

出版信息

Am J Clin Dermatol. 2025 Jan;26(1):147-150. doi: 10.1007/s40257-024-00897-6. Epub 2024 Oct 13.

DOI:10.1007/s40257-024-00897-6
PMID:39397142
Abstract
摘要

相似文献

1
Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study.口服罗氟司特治疗银屑病患者：一项真实世界队列研究。
Am J Clin Dermatol. 2025 Jan;26(1):147-150. doi: 10.1007/s40257-024-00897-6. Epub 2024 Oct 13.
2
Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study.口服罗氟司特治疗银屑病：一项为期24周的真实世界前瞻性队列研究。
J Dermatolog Treat. 2025 Dec;36(1):2464107. doi: 10.1080/09546634.2025.2464107. Epub 2025 Feb 11.
3
Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).银屑病患者口服罗氟司特治疗对体重和心脏代谢参数的影响 - 一项随机对照试验（PSORRO）的结果。
J Am Acad Dermatol. 2024 Jul;91(1):64-71. doi: 10.1016/j.jaad.2024.02.036. Epub 2024 Mar 1.
4
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).口服罗氟司特治疗中重度银屑病的疗效和安全性——一项随机对照试验（PSORRO）
Lancet Reg Health Eur. 2023 Apr 21;30:100639. doi: 10.1016/j.lanepe.2023.100639. eCollection 2023 Jul.
5
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.罗氟司特乳膏改善斑块状银屑病的体征和症状：一项 1/2a 期随机对照研究的结果。
J Drugs Dermatol. 2020 Aug 1;19(8):734-740. doi: 10.36849/JDD.2020.5370.
6
Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.罗氟司特乳膏在慢性斑块型银屑病中的药代动力学：来自 I 期至 III 期研究的数据。
Am J Clin Dermatol. 2023 Mar;24(2):315-324. doi: 10.1007/s40257-022-00741-9. Epub 2022 Nov 24.
7
Killing all the birds with one drug - is oral roflumilast a novel treatment option for psoriasis?一药灭众鸟——口服罗氟司特治疗银屑病的新选择？
J Dermatolog Treat. 2022 Sep;33(6):2782-2783. doi: 10.1080/09546634.2022.2069223. Epub 2022 Apr 28.
8
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.罗氟司特乳膏治疗慢性斑块状银屑病的试验。
N Engl J Med. 2020 Jul 16;383(3):229-239. doi: 10.1056/NEJMoa2000073.
9
[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review.[翻译文章] 皮肤病学中局部和口服罗氟司特：一篇叙述性综述。
Actas Dermosifiliogr. 2024 Mar;115(3):T265-T279. doi: 10.1016/j.ad.2024.01.009. Epub 2024 Jan 13.
10
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.每日一次的0.3%罗氟司特泡沫用于头皮和身体银屑病：一项随机、双盲、赋形剂对照的IIb期研究。
Br J Dermatol. 2023 Sep 15;189(4):392-399. doi: 10.1093/bjd/ljad182.

引用本文的文献

1
A systematic review of novel Phosphodiesterase-4 inhibitors in the treatment of psoriasis.新型磷酸二酯酶-4抑制剂治疗银屑病的系统评价
Inflamm Res. 2025 Aug 30;74(1):116. doi: 10.1007/s00011-025-02073-w.
2
Tapinarof Nanogels as a Promising Therapeutic Approach.他扎罗汀纳米凝胶作为一种有前景的治疗方法。
Pharmaceutics. 2025 Jun 1;17(6):731. doi: 10.3390/pharmaceutics17060731.

本文引用的文献

1
Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study.接受各种生物制剂治疗的银屑病患者的特征——一项丹麦队列研究
J Psoriasis Psoriatic Arthritis. 2024 Apr;9(2):51-60. doi: 10.1177/24755303241234292. Epub 2024 Feb 19.
2
A randomized, controlled pilot study of oral roflumilast compared with intramuscular methotrexate for plaque and scalp psoriasis.一项口服罗氟司特与肌肉注射甲氨蝶呤治疗斑块状和头皮银屑病的随机对照试验性研究。
J Am Acad Dermatol. 2024 May;90(5):1063-1065. doi: 10.1016/j.jaad.2024.01.018. Epub 2024 Jan 22.
3
Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.
针对先前生物制剂暴露的白介素-17A 抑制剂反应：一项丹麦全国性研究。
Acta Derm Venereol. 2023 Nov 21;103:adv12616. doi: 10.2340/actadv.v103.12616.
4
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).口服罗氟司特治疗中重度银屑病的疗效和安全性——一项随机对照试验（PSORRO）
Lancet Reg Health Eur. 2023 Apr 21;30:100639. doi: 10.1016/j.lanepe.2023.100639. eCollection 2023 Jul.
5
Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.全国性研究：生物治疗难治性银屑病和超应答者的流行情况及特征。
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1284-1291. doi: 10.1111/jdv.18126. Epub 2022 Apr 12.
6
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).银屑病治疗达标：利用一项基于人群的真实世界队列研究（英国皮肤科医师协会生物制剂和免疫调节剂登记处，BADBIR）的数据定义银屑病的治疗结果
Br J Dermatol. 2020 May;182(5):1158-1166. doi: 10.1111/bjd.18333. Epub 2019 Sep 10.